Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
作者信息
Ganan-Gomez Irene, Yang Hui, Ma Feiyang, Montalban-Bravo Guillermo, Thongon Natthakan, Marchica Valentina, Richard-Carpentier Guillaume, Chien Kelly, Manyam Ganiraju, Wang Feng, Alfonso Ana, Chen Shuaitong, Class Caleb, Kanagal-Shamanna Rashmi, Ingram Justin P, Ogoti Yamini, Rose Ashley, Loghavi Sanam, Lockyer Pamela, Cambo Benedetta, Muftuoglu Muharrem, Schneider Sarah, Adema Vera, McLellan Michael, Garza John, Marchesini Matteo, Giuliani Nicola, Pellegrini Matteo, Wang Jing, Walker Jason, Li Ziyi, Takahashi Koichi, Leverson Joel D, Bueso-Ramos Carlos, Andreeff Michael, Clise-Dwyer Karen, Garcia-Manero Guillermo, Colla Simona
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.
出版信息
Nat Med. 2022 May;28(5):1097. doi: 10.1038/s41591-022-01827-x.
Abstract
摘要
相似文献
1
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.作者更正：干细胞结构驱动骨髓增生异常综合征进展并预测基于维奈托克的治疗反应。
Nat Med. 2022 May;28(5):1097. doi: 10.1038/s41591-022-01827-x.
2
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.干细胞结构驱动骨髓增生异常综合征的进展，并预测对基于 venetoclax 的治疗的反应。
Nat Med. 2022 Mar;28(3):557-567. doi: 10.1038/s41591-022-01696-4. Epub 2022 Mar 3.
3
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Venetoclax 联合克拉屈滨、伊达比星和阿糖胞苷强化化疗治疗初诊急性髓系白血病或高危骨髓增生异常综合征患者：来自单中心、单臂、2 期临床试验的一个队列研究。
Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.
4
Bladder Myeloid Sarcoma with mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen.伴有骨髓增生异常综合征/骨髓增殖性肿瘤重叠综合征突变的膀胱髓系肉瘤：对地西他滨-维奈克拉方案的反应
Leuk Res Rep. 2021 Dec 14;17:100286. doi: 10.1016/j.lrr.2021.100286. eCollection 2022.
5
Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax.维奈克拉治疗依赖输血的骨髓增生异常综合征
Case Rep Hematol. 2020 Mar 12;2020:9031067. doi: 10.1155/2020/9031067. eCollection 2020.
6
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.在异基因造血细胞移植之前和之后的 AML 和高危 MDS 中基于 Venetoclax 的联合治疗。
Leuk Lymphoma. 2021 Dec;62(14):3394-3401. doi: 10.1080/10428194.2021.1966788. Epub 2021 Sep 3.
7
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.阿扎胞苷联合维奈托克治疗高危骨髓增生异常综合征或慢性粒单核细胞白血病患者的单中心、剂量递增和剂量扩展 1-2 期研究的 1 期结果。
Lancet Haematol. 2022 Oct;9(10):e756-e765. doi: 10.1016/S2352-3026(22)00216-2. Epub 2022 Sep 2.
8
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.高危骨髓增生异常综合征和急性髓系白血病患者用维奈克拉治疗的真实土耳其经验。
Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20.
9
Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience.阿扎胞苷和维奈克拉的临床疗效以及Tim-3和半乳糖凝集素-9对急性髓系白血病和高危骨髓增生异常综合征的预后影响：一项单中心真实世界经验。
Front Pharmacol. 2022 Dec 21;13:1052060. doi: 10.3389/fphar.2022.1052060. eCollection 2022.
10
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.异基因造血干细胞移植后髓系恶性肿瘤复发的治疗：维奈托克联合低甲基化药物的回顾性多中心分析-代表德国合作移植研究组。
Ann Hematol. 2021 Apr;100(4):959-968. doi: 10.1007/s00277-020-04321-x. Epub 2020 Nov 16.
引用本文的文献
1
A Genetically-Informed Network Model of Myelodysplastic Syndrome: From Splicing Aberrations to Therapeutic Vulnerabilities.骨髓增生异常综合征的基因信息网络模型：从剪接异常到治疗易感性
Genes (Basel). 2025 Aug 1;16(8):928. doi: 10.3390/genes16080928.
2
Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS.从克隆性造血到骨髓增生异常综合征的造血结构的进行性破坏。
iScience. 2023 Jul 10;26(8):107328. doi: 10.1016/j.isci.2023.107328. eCollection 2023 Aug 18.
Zotero 插件